人补体衰变加速因子、补体膜辅助调节蛋白及CD59真核表达载体构建及序列分析

目的:构建人补体衰变加速因子(Decayacceleratingfactor,DAF)、补体膜辅助调节蛋白(membranecofactorprotein,MCP)、CD59的真核表达载体pSecTag2/HygroB-DAF、pSecTag2/HygroB-MCP、pSecTag2/HygroB-CD59。方法:应用PCR方法,从DAF-pGEM-TEasyVector、MCP-pGEM-TEasyVector和CD59-pGEM-TEasyVector分别克隆所需的DNA片段,经限制性内切酶BglandXhol消化后,插入到具有相应酶切位点的真核表达载体pSecTag2/HygroB中,分别构建人DAF、MCP、CD59真核表达质粒,并进行酶切鉴定及DNA序列测定分析。结果:DAF基因大小为1049bp,MCP基因大小为1065bp,CD59基因大小为312bp,与genbank中记载的人DAF、MCP和CD59cDNA序列结果基本相同。结论:成功构建DAF、MCP和CD59真核表达质粒,为今后进一步探讨及研究转基因肝脏奠定了基础。     

复方五仁醇胶囊含药血清药源性成分分析

目的:分析大鼠服复方五仁醇胶囊后血清中的药源性成分。方法:以已经建立的高效液相色谱指纹图谱分析方法,比较复方五仁醇胶囊含药血清色谱图和空白血清色谱图,分辨该制剂给药后血清中产生的药源性成分,并通过对照品比对部分成分进行鉴定。结果:灌胃给药后血清中产生药源性成分13个,其中8个为制剂原形成分,包括五味子醇甲、五味子甲素、五味子乙素,其余5个为代谢产物。结论:复方五仁醇胶囊体内直接作用物质很可能出自血清中的13个药源性成分,结合血清药理学对其作进一步研究有助于阐明该制剂药效物质基础。     

结核病相关信息获得途径的调查分析

目的 了解人群获得结核病防治知识的主要渠道，为结核病控制健康促进策略提供依据。方法 采取问卷调查的方法对抽取的4个省的2449名被调查居民、888名肺结核病、838名肺结核可疑症状者进行结核病相关信息途径的调查。结果 39．2％的居民结核病相关信息是通过聊天获得的，54．8％的肺结核病患者和34．5％的可疑结核病症状者是听医生介绍的。结论 群众获得结核病防治信息的主要渠道是聊天和听医生介绍。应积极开展面对面的宣传，发挥社区干部、基层医生和电视传播在结核病防治宣传中的作用，促进结核病防治知识普及。     

百令胶囊对实验性糖尿病大鼠肾脏的保护作用

目的：探讨百令胶囊对实验性糖尿病大鼠肾脏的保护作用。方法：SD大鼠45只，分为正常对照组、糖尿病对照组及糖尿病治疗组。各糖尿病组以四氧嘧啶腹腔内注射制成糖尿病模型。治疗组大鼠给予给予百令胶囊0．2g／kg／天灌胃，每天1次，共12周。取肾脏行光镜和电镜检查，并进行图像分析，同时行血糖、血脂、肾功能、24h尿蛋白排泄量、肾重／体重、肾组织糖基化产物测定。统计学处理采用方差分析。结果与糖尿病对照组比较，治疗组大鼠血TG、TC、肾重／体重、24h尿蛋白排泄量以及肾脏组织蛋白糖基化产物水平均有不同程度的降低（P〈0．05）。与正常对照组比较，光镜检查显示糖尿病对照组大鼠肾小球截面积明显增大（P〈0．01），系膜区基质增生扩大；肾小球硬化明显，平均肾小球硬化指数明显增加（P〈0．01）；电镜显示大鼠肾小球基底膜显著的不均匀增厚，并伴有广泛的肾小管上皮细胞的髓样变性及胞浆空泡化变性。治疗组上述病变明显减轻（P〈0．01）。结论：百令胶囊显著改善糖尿病大鼠肾脏结构，防止系膜区扩大和基底膜增厚，具有显著地抗肾小球纤维化的作用。     

ELISA法与MEIA法快速定量检测肝移植患者乙肝免疫球蛋白滴度

目的:比较微粒子酶免疫法(MEIA)和酶联免疫法(ELISA)检测肝移植患者乙肝免疫球蛋白滴度(HBIG)的特点,总结其在II临床HBIG滴度检测中的应用.方法:分别以MEIA和ELISA平行测定50,100,500IU·L-1的HBIG标准品,比较两种方法的准确度、精密度、相关性及各自特点.结果:MEIA和ELISA方法学的回收率分别为(105.32±1.85)%和(103.71±3.76)%,RSD分别为(3.67±2.30)%和(2.75±0.74)%.检测HBIG滴度≤160IU·L-1时,两个方法的相关性为CMEIA=0.709CELISA 30.142,r=0.784 0(n=26).当HBIG滴度＞160IU·L-1时,两方法检测结果CMEIA=-0.010CELISA 159.197,r=0.032 0(n=29).结论:ELISA法可用于常规的HBIG检测,而MEIA的检测范围比较宽,不仅可用于常规HBIG的检测,更适合HBIG被动免疫后人群的临床监测.     

酸枣仁汤药效的影响因素研究

目的　对影响酸枣仁汤药效的因素进行研究。方法　采用均匀设计的方法 ,以旷野法的自发活动次数为指标 ,对影响酸枣仁汤药效的三个因素 :药物剂量、起效时间及给药天数进行研究。结果　三个因素中对自发活动次数影响大小依次为 :给药天数 >起效时间。在选定的剂量范围内 ,自发活动次数与剂量之间无线性关系 ;与给药天数、给药后起效时间有依赖关系 ,且给药天数、给药后起效时间与自发活动次数呈正相关。结论　自发活动次数最少的因素组合为 :给药 1天 ,给药后30min后进行实验 ,药物剂量为 12g/kg。为本方的药理研     

舒筋活络洗剂治疗骨折后关节挛缩的临床研究

为客观评价舒筋活络洗剂治疗骨折后关节挛缩的作用及不良反应.将100例骨折后关节挛缩的患者随机均分为治疗组和对照组,治疗组用舒筋活络洗剂,对照组有红花油,分别于用药后3、5、7天进行评分,并将评分结果统计分析.结果显示:①治疗组显愈率为88.00%,对照组显愈率为54.00%,两组比较(P《0.01),治疗组对于症候的改善作用优于对照组;②舒筋活络洗剂无毒副作用.表明舒筋活络洗剂是治疗骨折后关节挛缩有效而且安全的药物.     

The disease characteristics of patients both with IgA nephropathy and diabetes mellitus

Objective To sum up and analyze the clinical and pathological characteristics in patients with both IgA nephropathy (IgAN) and diabetes mellitus. Methods A total of 500 patients were recruited, including 25 patients with both IgAN and diabetes mellitus, and 475 patients with IgAN only, who were diagnosed by renal-biopsy during Jan 2015 to Jan 2017 at the First Affiliated Hospital of Zhengzhou University. The clinical and pathological data were collected and analyzed using SPSS 22.0. Propensity Score Matching was used to match and select the patients in the both groups, and thereafter the depth of the basement membrane from the matched patients were compared using electron microscopy. The data of the patients whose follow-up time was ≥3 months were retrospectively collected, and Kaplan-Meier analysis was used to compare the difference of the prognosis. Results Compared to the patients with IgAN only, patients with both IgAN and diabetes mellitus were older [(46.36±13.49) years vs (34.00±13.80) years, P＜0.001], had higher level of serum triglyceride [2.06(1.52, 3.11) mmol/L vs 1.51(1.01, 2.25) mmol/L, P=0.012] and thicker basement membrane [(384.33±61.20) nm vs (346.72±52.65) nm, P=0.044]. The patients with both IgAN and diabetes mellitus were more prone to reach the composite endpoint [4/7(57.14%) vs 25/265(9.33%), P＜0.001] and had worse prognosis (Log-Rank test, P=0.004). Conclusions IgAN patients with diabetes mellitus have different clinical, pathological characteristics and prognosis from patients with IgAN alone. These patients need to be closely monitored and actively treated.     

Melatonin mediates protective effects on inflammatory response induced by interleukin‐1 beta in human mesenchymal stem cells

Joint diseases like osteoarthritis usually are accompanied with inflammatory processes, in which pro‐inflammatory cytokines mediate the generation of intracellular reactive oxygen species (ROS) and compromise survival of subchondral osteoblasts. Melatonin is capable of manipulating bone formation and osteogenic differentiation of mesenchymal stem cells (MSCs). The aim of this work was to investigate the anti‐inflammatory effect of melatonin on MSC proliferation and osteogenic differentiation in the absence or presence of interleukin‐1 beta (IL‐1β), which was used to induce inflammation. Our data showed that melatonin improved cell viability and reduced ROS generation in MSCs in a dose‐dependent manner. When exposed to 10 ng/mL IL‐1β, various concentrations of melatonin resulted in significant reduction of ROS by 34.9% averagely. Luzindole as a melatonin receptor antagonist reversed the anti‐oxidant effect of melatonin in MSCs with co‐exposure to IL‐1β. Real‐time RT‐PCR data suggested that melatonin treatment up‐regulated the expression of CuZnSOD and MnSOD, while down‐regulated the expression of Bax. To investigate the effect of melatonin on osteogenesis, MSCs were cultured in osteogenic differentiation medium supplemented with IL‐1β, melatonin, or luzindole. After exposed to IL‐1β for 21 days, 1 μm melatonin treatment significantly increased the levels of type I collagen, ALP, and osteocalcin, and 100 μm melatonin treatment yielded the highest level of osteopontin. Our study demonstrated that melatonin maintained MSC survival and promoted osteogenic differentiation in inflammatory environment induced by IL‐1β, suggesting melatonin treatment could be a promising method for bone regenerative engineering in future studies.